LexaGene Places MiQLab System at the University of Pennsylvania’s School of Veterinary Medicine
November 18 2020 - 7:58AM
LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the
“
Company”), a molecular diagnostics company that
develops fully automated rapid pathogen detection systems, is
pleased to announce that it has placed a MiQLab™ system into the
clinical microbiology laboratory at the University of
Pennsylvania’s School of Veterinary Medicine (Penn Vet) as part of
its Early Access Program. Penn Vet provides testing for animal
patients at both the Ryan Veterinary Hospital and patients of
practices across the US, processing thousands of samples each year.
Dr. Jack Regan, LexaGene’s CEO and Founder, states, “We are very
excited to be placing our first completed commercial MiQLab system
in the Penn Vet microbiology laboratory for their evaluation. This
is a tremendous step in delivering our technology into the
veterinary market and beyond.”
The MiQLab system represents a true breakthrough for veterinary
medicine as there is currently no technology available that has
been designed for in-clinic, point-of-care multiplex testing for
pathogens and markers of antibiotic resistance. This new technology
will empower veterinarians to make faster, evidence-based treatment
decisions for greater confidence in the therapies they are
prescribing.
LexaGene’s Early Access Program is an opportunity for
forward-looking veterinarians to gain early access to the
commercial application of the technology to significantly improve
their current turnaround times for testing.
Dr. Shelley Rankin, Professor of Microbiology, Head of
Diagnostic Services and Chief of Clinical Microbiology at Penn Vet,
states, “My laboratory is looking forward to evaluating this fully
automated instrument that will allow us to rapidly test clinical
samples by PCR to identify pathogens and antimicrobial resistance
factors. I’ve been in this field for many years and I am passionate
about advancing diagnostics. LexaGene’s technology is the first
automated PCR technology available in the veterinary field and the
closest I’ve seen to a “STAT” microbiology test. I’m very excited
to have this unique opportunity to evaluate the MiQLab at Penn Vet.
I hope that it will provide us with the ability to quickly return
results to clinicians, which will have a significant impact on
patient treatment decisions and antimicrobial stewardship in
veterinary medicine.”
The initial application of MiQLab focuses on the rapid detection
of 20 targets that include common bacterial pathogens infecting
companion animals and their associated antimicrobial resistance
markers of therapeutic and public health significance. Penn Vet
will evaluate the instrument with a range of specimen types, and
data collected from the MiQLab will be used to help further
determine sensitivity, specificity, and antimicrobial concordance
of the test in relation to clinical standards.
To be added to the LexaGene email list, please subscribe on the
Company website.
On Behalf of the Board of DirectorsDr.
Jack ReganChief Executive Officer
& Director
About LexaGene Holdings Inc.LexaGene is a
molecular diagnostics company that develops molecular diagnostic
systems for pathogen detection and genetic testing for other
molecular markers for on-site rapid testing in veterinary
diagnostics, food safety and for use in open-access markets such as
clinical research, agricultural testing and biodefense. End-users
simply need to collect a sample, load it onto the instrument with a
sample preparation cartridge, enter sample ID and press ‘go’. The
MiQLab™ system delivers excellent sensitivity, specificity, and
breadth of detection and can return results in approximately one
hour. The unique open-access feature is designed for custom testing
so that end-users can load their own real-time PCR assays onto the
instrument to target any genetic target of interest.
For further information, please contact:
Media ContactsNicole RidgedaleDirector of
Corporate Marketing, LexaGene800.215.1824 ext
206nridgedale@lexagene.com
Investor RelationsJay AdelaarVice President of
Capital Markets, LexaGene800.215.1824 ext
207jadelaar@lexagene.com
The TSX Venture Exchange Inc. has in no way
passed upon the merits of the proposed transaction and has neither
approved nor disapproved the contents of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
This news release contains forward-looking information, which
involves known and unknown risks, uncertainties and other factors
that may cause actual events to differ materially from current
expectation. Important factors -- including the availability of
funds, the results of financing efforts, the success of technology
development efforts, the cost to procure critical parts,
performance of the instrument, market acceptance of the technology,
regulatory acceptance, and licensing issues -- that could cause
actual results to differ materially from the Company's expectations
as disclosed in the Company's documents filed from time to time on
SEDAR (see www.sedar.com). Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. The company disclaims
any intention or obligation, except to the extent required by law,
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jul 2023 to Jul 2024